Bucinnazine AP-237 AP237 CAS: 17719-89-0

CAS NO: 17719-89-0
Our products are for experimental study only
Bucinnazine AP-237 AP237
Chemical Name: AP-237
Molecular Formula: C17H24N2O
Formula Weight: 272.39
CAS No.: 17719-89-0
Description Review
Description
Our products are for experimental study only

Bucinnazine AP-237, also known as AP237, is a synthetic opioid analgesic that has recently gained popularity as a recreational drug. It has been found to have high potency and efficacy in alleviating pain, but it also carries a high risk of addiction and overdose.

Chemical Name

The chemical name of Bucinnazine AP-237 is N-(1-Benzylpiperidin-4-yl)-N-phenylpropanamide.

Molecular Formula

The molecular formula of Bucinnazine AP-237 is C22H28N2O.

Formula Weight

The formula weight of Bucinnazine AP-237 is 332.47 g/mol.

CAS No.

The CAS number for Bucinnazine AP-237 is 17719-89-0.

Top Ten Keywords and Synonyms from Google

  1. Synthetic opioid
  2. Analgesic
  3. Recreational drug
  4. High potency
  5. Addiction
  6. Overdose
  7. Pain relief
  8. Central nervous system depression
  9. Respiratory depression
  10. NMDA receptor antagonist

Health Benefits of Bucinnazine AP-237

Bucinnazine AP-237 has primarily been used for its analgesic properties, with high potency and efficacy in alleviating pain. However, because of its potential for addiction and overdose, it is not recommended for use as a pain medication.

Potential Effects

Bucinnazine AP-237 has several potential effects, including:

  1. Pain relief: Bucinnazine AP-237 may alleviate pain more effectively than other opioids due to its high potency.
  2. Euphoria: Bucinnazine AP-237 can produce feelings of intense happiness and well-being.
  3. Sedation: Bucinnazine AP-237 can cause sedation and drowsiness.
  4. Respiratory depression: Bucinnazine AP-237 can cause respiratory depression, which can be fatal in high doses.

Product Mechanism

Bucinnazine AP-237 works by binding to opioid receptors in the brain and spinal cord, inhibiting the transmission of pain signals and producing feelings of euphoria. It also acts as an NMDA receptor antagonist, further reducing the sensation of pain.

Safety

Bucinnazine AP-237 is not considered safe for use as a pain medication due to its high potential for addiction and overdose. It should only be taken under the guidance of a healthcare professional and in strict accordance with dosing instructions. It should never be taken with alcohol or other central nervous system depressants, as this can increase the risk of respiratory depression and fatal overdose.

Side Effects

The side effects of Bucinnazine AP-237 may include:

  1. Dizziness
  2. Nausea
  3. Vomiting
  4. Constipation
  5. Respiratory depression
  6. Hypotension
  7. Seizures

Dosing Information

The dosing of Bucinnazine AP-237 varies depending on the individual's condition and response to treatment. It is usually taken orally, and the recommended dose ranges from 10-20 mg per day. The dose may be adjusted based on the individual's body weight and overall health.

Conclusion

Bucinnazine AP-237 is a synthetic opioid analgesic that has gained popularity as a recreational drug. While it has high potency and efficacy in alleviating pain, it also carries a high risk of addiction and overdose. It should only be taken under the guidance of a healthcare professional and in strict accordance with dosing instructions. If you are experiencing severe pain or other health conditions, it is important to seek medical attention and follow the guidance of healthcare professionals.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code